The Trump administration has imposed a 15% tariff on EU pharmaceuticals and threatened even steeper levies elsewhere. At the same time, however, the government has issued ultimatums to 17 companies to cut drug costs. In this podcast, ING's Diederik Stadig explains why these competing goals cannot be reconciled, and what the strategy means for the industry - and for consumers in the US and Europe.